Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05516992
Other study ID # SB01-M001
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date August 19, 2022
Est. completion date June 1, 2025

Study information

Verified date May 2024
Source Spine BioPharma, Inc
Contact Pamela Zicker, NP
Phone 831-239-4115
Email pzicker@spinebiopharma.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of the study is to confirm the safety and effectiveness of SB-01 For Injection in adult patients with chronic low back pain and related disability due to Lumbar Degenerative Disc Disease. The primary effectiveness hypothesis is superiority of the investigational product relative to control in terms of the percentage of subjects improving in pain-related disability.


Recruitment information / eligibility

Status Recruiting
Enrollment 400
Est. completion date June 1, 2025
Est. primary completion date December 1, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. 18 years of age or older 2. Back pain greater than 'worst leg pain' as measured by the NRS 3. Diagnosed with one or two contiguous level(s) lumbar (L1-S1) disc degeneration of Pfirrmann Grade 3 and/or 4 determined by MRI analyzed by the independent radiologic central lab 4. Have chronic low back pain and related disability for at least 6 months with at least 3 months of prior conservative treatment 5. Baseline ODI score = 40/100 6. Baseline NRS = 4 points (Back) 7. Willing and able to provide Informed Consent for study participation 8. Willing and able to comply with this protocol and be available for the entire duration of the study, including ability to access the internet 9. Must practice effective contraception during the first 3 months of follow-up (female of childbearing potential and male subjects): 1. Abstinence or, 2. Surgical Sterilization or, 3. Oral Contraceptives or, 4. Barrier Methods (Condoms, IUD's). 10. Patient must verify that: 1. In the case of females, the patient is post-menopausal or is surgically sterile or, 2. In the case of males, the patient is surgically sterile or, 3. The patient (male or female) confirms that they are at a point in their life where they are beyond consideration of having children. Exclusion Criteria: To qualify for enrollment in this study, patients must meet none of the exclusion criteria as follows. 1. Prior epidural, sacroiliac joint, or facet injections at any lumbosacral level within the past 4 weeks (e.g., transforaminal, interlaminar, caudal) 2. Prior interventional procedures of other types at any lumbosacral level at any time (e.g., intradiscal injection, basivertebral nerve ablation, biacuplasty; radiofrequency (RF) ablation, spinal cord stimulator, others) 3. Prior spine surgery at any lumbosacral level at any time (e.g., discectomy, decompression, instrumentation, fusion, fracture treatment, others) 4. Prior fracture at any lumbar level 5. Significant neurologic symptoms: 1. Grade 3/5 or lower strength in any lumbar myotome 2. Sensory deficit in a clearly radicular or sensory dermatome 6. MRI evidence of disc height loss > 2/3 of adjacent disc at any level to be injected, determined by the independent radiologic central lab 7. MRI evidence of other disc degeneration: Pfirrmann Grade 3-5 at any level not to be injected, determined by the independent radiologic central lab 8. MRI evidence of disc herniation with neural compression at any level, determined by the independent radiologic central lab 9. MRI evidence of significant stenosis of the central canal at any level, determined by the independent radiologic central lab 10. MRI evidence of foraminal stenosis with neural compression at any level, determined by the independent radiologic central lab 11. MRI evidence of moderate-to-severe facet arthrosis with edema at any level, determined by the independent radiologic central lab 12. Spondylolisthesis (antero or retrolisthesis) > 25% at any level, determined by the independent radiologic central lab 13. Lumbar coronal deformity, determined by the independent radiologic central lab: a. L1-S1 regional deformity > 25 degrees 14. Spondylolysis at any level 15. Lumbar inflammatory spondylitis 16. Recent history (previous six months) of chemical or alcohol dependence 17. Chronic narcotic use for more than defined as a daily dose of greater than 40 Morphine Equivalent Units (MEUs) 18. Depression or Somatization defined through the Distress and Risk Assessment Method (DRAM) scoring with Zung score > 33 or Zung > 17 and the Modified Somatic Perception Questionnaire (MSPQ) score > 12 19. Extreme obesity, defined by NIH Clinical Guidelines Body Mass Index (BMI > 40) 20. A QT duration corrected for heart rate by Fridericia's formula (QTcF) > 470 millisecond (msec) 21. Active systemic infection 22. Infection at the site of procedure pre-operatively 23. Cauda equina syndrome or neurogenic bowel/bladder dysfunction 24. Any terminal, systemic, or autoimmune disease including fibromyalgia, which may, in the opinion of the Principal Investigator compromise a subject's ability to comply with study procedures, and/or confound data 25. Metabolic bone disease (e.g., osteoporosis/osteopenia, gout, osteomalacia, Paget's disease) 26. Any disease, condition or surgery which might impair healing, such as: 1. Active malignancy 2. History of metastatic malignancy 27. Currently experiencing an episode of major mental illness (psychosis, major affective disorder, or schizophrenia), or manifesting physical symptoms without a diagnosable medical condition to account for the symptoms, which may indicate symptoms of psychological rather than physical origin 28. Any planned surgical procedure within the subject participation period (screening through the 12 Month Visit) 29. Any clinically relevant laboratory result on the screening visit Chem-12, hematology, or coagulation panels 30. Pregnancy at the time of screening, randomization, or planning to become pregnant during the first 3 months of follow-up 31. Currently a prisoner 32. Participation in any other investigational drug, biologic, or medical device study within the last 6 months prior to study procedure 33. Receiving Work Compensation benefits or engaged in personal spinal injury medical/legal litigation 34. Patient cannot be currently using the prohibited medications listed in the protocol

Study Design


Intervention

Drug:
SB-01 For Injection
Intradiscal injection
Sham Needle
Sham needle placement

Locations

Country Name City State
United States HD Research Bellaire Texas
United States Central Alabama Research Birmingham Alabama
United States Injury Care Research Boise Idaho
United States Montefiore Medical Center Bronx New York
United States HD Research at Legent Orthopedic Hospital Carrollton Texas
United States Pain Management Center, Brigham and Women's Hospital Chestnut Hill Massachusetts
United States META Medical Research Institute Dayton Ohio
United States Science Connections, LLC Doral Florida
United States Clinical Investigations LLC Edmond Oklahoma
United States NeuroCare Partners Houston Texas
United States The Orthopaedic Research Foundation, Inc (OrthoIndy) Indianapolis Indiana
United States Coastal Clinical Research Jacksonville Florida
United States Kettering Health Kettering Ohio
United States Neurovations Research Napa California
United States Duly Health Naperville Illinois
United States Ainsworth Institute of Pain Management New York New York
United States Mount Sinai Hospital New York New York
United States Pioneer Clinical Research New York New York
United States Vista Clinical Research, LLC Newnan Georgia
United States Southern California (SC) Spine and Sport Medical Associates, Inc. Newport Beach California
United States OrthoNebraska Omaha Nebraska
United States Conquest Research Orlando Florida
United States Conquest Research Orlando Florida
United States Four Rivers Clinical Research Paducah Kentucky
United States Evolve Clinical Research Phoenix Arizona
United States Virginia iSpine Physicians Richmond Virginia
United States Pain Relief Centers Saint Petersburg Florida
United States University of Utah Salt Lake City Utah
United States Wasatch Clinical Research Salt Lake City Utah
United States South Texas Spinal Clinic San Antonio Texas
United States Pacific Research Institute San Diego California
United States Scripps Health San Diego California
United States Central Coast Neurological Surgery San Luis Obispo California
United States Source Healthcare Santa Monica California
United States Arizona Pain Scottsdale Arizona
United States Spine Institute of Louisiana Shreveport Louisiana
United States Florida Pain Relief Group Tampa Florida
United States Tampa Pain Relief Center Tampa Florida
United States The Orthopedic Center Tulsa Oklahoma
United States Precision Spine Care Tyler Texas
United States Gershon Pain Specialists Virginia Beach Virginia
United States Tranquil Clinical Research Webster Texas
United States Abay Neuroscience Center Wichita Kansas
United States Conquest Research Winter Park Florida

Sponsors (2)

Lead Sponsor Collaborator
Spine BioPharma, Inc MCRA

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from Baseline in function on the Oswestry Disability Index (ODI) at 6 months. The ODI is a validated, 10-item self-reported instrument assessment of pain-related disability. Possible scores range from 0 (no disability) - 50 (severe disability). Further calculations are applied to reach a percentage score. Baseline/Screening and 6 Month
Secondary Change from Baseline in pain on the Numerical Rating Scale (NRS) at 6 months. This outcome will only be tested if the primary endpoint is met. The NRS is an 11-point scale, self-reported instrument assessment of pain intensity ranging across a continuum from no pain to an extreme amount of pain. The NRS will be collected for: Back and both legs. A lower score indicates less pain. Baseline/Screening and 6 Month
See also
  Status Clinical Trial Phase
Completed NCT01198470 - TRIUMPH Lumbar Artificial Disc IDE: A Pilot Study N/A
Terminated NCT00744861 - Ultrasound as Adjunct Therapy for Increasing Fusion Success After Lumbar Surgery N/A
Completed NCT00949936 - Safety and Performance Study of the CAdiscTM-L Lumbar Spinal Disc Replacement Device For CE Marking N/A
Completed NCT03974711 - Rampart Duo Clinical (RaDical) Post-Market Study
Recruiting NCT01721889 - Radiostereometric Analysis of Spine Arthrodesis N/A
Terminated NCT02139527 - CARES Lumbar Artificial Disc Registry Phase 4
Terminated NCT00878579 - Percutaneous Dynamic Stabilization (PDS) System Versus Fusion for Treating Degenerative Disc Disease Phase 2
Completed NCT01640977 - A Prospective Non-concurrent Controlled Evaluation of Open and MAS® PLIF N/A
Terminated NCT01689922 - The Effectiveness of Anti-Gravity Treadmill Training N/A
Enrolling by invitation NCT02529566 - Human Autograft Mesenchymal Stem Cell Mediated Stabilization of The Degenerative Lumbar Spine N/A
Completed NCT02347410 - Spineology Clinical Outcomes Trial: An IDE Investigation N/A
Terminated NCT02070484 - Human Amniotic Tissue-derived Allograft, NuCel, in Posteriolateral Lumbar Fusions for Degenerative Disc Disease N/A
Terminated NCT01294007 - Radiographic Analysis Using PureGen Versus Autologous Bone in Posterolateral Fusion (PLF) N/A
Terminated NCT01293981 - Radiographic and Clinical Outcomes of PureGen in Posterior Lumbar (PLIF) and Transforaminal Interbody Fusion (TLIF) N/A
Terminated NCT00640029 - Evaluation of the Prosthetic Disc Replacement N/A
Terminated NCT00456378 - Study of the Safety and Effectiveness of DIAMâ„¢ Spinal Stabilization System Versus Conservative Care N/A
Completed NCT03647501 - Lumbar Fusion With Nexxt Spine 3D-Printed Titanium Interbody Cages N/A
Active, not recruiting NCT02297256 - Prospective Study of Thoracolumbar Spinal Fusion Graft N/A
Completed NCT01323387 - Lumbar Degenerative Disc Disease Treated With Anterior Tension Band System (ATB) With ALIF/FRA Spacer N/A